As expected, the US FDA gave its OK for Exelixis to market its tyrosine kinase inhibitor Cometriq (cabozantinib) as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC) – a decision that came after the US markets closed on 29 November.
The first sign the company's application was moving smoothly through the review process was when the FDA decided not to have its Oncologic Drugs Advisory Committee scrutinize the new drug application for the medicine (scripintelligence,
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?